1. GENTA (GNTA) www.genta.com Recent stock price: 12.44 (2/17/04 close) 52-wk range: 5.50 – 17.65 Market cap: 923 Mil Diluted EPS: - 0.66 Revenue: 5.2 Mil ttm Expenses: - 66 Mil ttm Net income: - 61 Mil ttm Revenue Growth: 2337% ttm Est. target price: 16.25 Founded: 1988 Berkley Heights, NJ Employees: 96 Analyst recommendations: neutral/mkt perform “ 2.0 / 5.0“ (1= Strong buy, 5 = Strong sell) Analyst upgrades Genasense P-III results Analyst down grades NDA filed State visit Analyst reports

2. Genasense Ganite Androgenics Oral Gallium Decoy Discovery Formulation Ph1 Ph2 Ph3 Market Products

3. Genasense—Antisense Bcl-2 to inhibit tumor growth. Overexpression of Bcl-2 is a major contributing factor to the development of drug resistance in cancer patients undergoing chemotherapy, radiation, or monoclonal antibody treatment. Most tumors express high levels of Bcl-2, therefore inactivation of Bcl-2 is a feasible target to sensitize cancer cells to these therapies. Phase III trials show 2-month increase in survival rate for melanoma patients. NDA filed in Dec 2003 for malignant melanoma and has fast-track designation. Phase I and II trials are ongoing for CLL, MML (2004 NDA, orphan drug status), prostate (2005), NSCLC (2006), NHL (2006), colon (2007) and breast (2007). $477 Mil collaboration with Aventis to develop Genasense. Ganite—FDA approved drug consisting of elemental gallium delivered intravenously for the treatment of cancer-related hypercalcemia (excessive buildup of calcium in the bloodstream). Because gallium also acts as a ribonucleotide reductase inhibitor, an IND has been filed for Ganite treatment of Non-Hodgkin’s Lymphoma. Oral Gallium—Gallium also incorporates into metabolically active bone where it can inhibit bone resorption. An oral formulation is being developed for low-dose extended-use treatment to maintain bone integrity over long- term periods. Currently in Preclinical development. Androgenics—Small molecule compounds that inhibit testosterone production for hormone-dependent prostate cancer treatment. Currently in Preclinical development. CREBP Decoy—Modified strands of DNA or RNA bases with increased half-life that act as a decoy for cyclic AMP response element (CRE)-binding protein. Preclinical studies indicate this drug can selectively inhibit cancer cell growth.

7. GNTA vs. ISIS GNTA vs. BTK GNTA vs. LORFF

8. DIRECT COMPETITOR COMPARISON GNTAISISLORFFINDUSTRY Market Cap:1.0B480 M137 M215 M Employ­ees:9652352117 Rev. Growth (ttm):2337%51%11% Gross Margin (ttm):100%100%88%95% EBITDA (ttm):-58.7M-68.7M-16.4M-18.0M Net Income (ttm):-59.9M-86.1M-17.0M-20.9M EPS (ttm):-0.81-1.56-0.11-0.71 PS (ttm):190.17.4273.513.7 GNTA = Genta Inc. ISIS = Isis Pharmaceuticals LORFF.OB = Lorus Therapeutics Inc